1023 related articles for article (PubMed ID: 26343012)
41. MicroRNA-30a Modulates Type I Interferon Responses to Facilitate Coxsackievirus B3 Replication
Li J; Xie Y; Li L; Li X; Shen L; Gong J; Zhang R
Front Immunol; 2020; 11():603437. PubMed ID: 33519812
[TBL] [Abstract][Full Text] [Related]
42. Cardiomyocyte-specific deletion of Senp2 contributes to CVB3 viral replication and inflammation.
Wang K; Jiang Z; Lu X; Zhang Y; Yuan X; Luo D; Lin Z; Zuo Y; Luo Q
Int Immunopharmacol; 2020 Nov; 88():106941. PubMed ID: 33182061
[TBL] [Abstract][Full Text] [Related]
43. Expression of immunoregulatory cytokines by recombinant coxsackievirus B3 variants confers protection against virus-caused myocarditis.
Henke A; Zell R; Ehrlich G; Stelzner A
J Virol; 2001 Sep; 75(17):8187-94. PubMed ID: 11483764
[TBL] [Abstract][Full Text] [Related]
44. Vγ1
Wan F; Yan K; Xu D; Qian Q; Liu H; Li M; Xu W
Mol Immunol; 2017 Jan; 81():16-25. PubMed ID: 27886550
[TBL] [Abstract][Full Text] [Related]
45. Tanshinone IIA Ameliorate Coxsackie Virus B3-Induced Viral Myocarditis through the Inhibition of Inflammation and Modulation T Helper 1/T Helper 2 Balance in Mice.
Guo G; Zhao Q; Wang Q; Li E
Pharmacology; 2019; 103(3-4):136-142. PubMed ID: 30602153
[TBL] [Abstract][Full Text] [Related]
46. Cleavage of osmosensitive transcriptional factor NFAT5 by Coxsackieviral protease 2A promotes viral replication.
Qiu Y; Ye X; Zhang HM; Hanson P; Zhao G; Tong L; Xie R; Yang D
PLoS Pathog; 2017 Dec; 13(12):e1006744. PubMed ID: 29220410
[TBL] [Abstract][Full Text] [Related]
47. Effect of prophylactically applied CpG ODN on the development of myocarditis in mice infected with Coxsackievirus B3.
Zhao T; Wu X; Song D; Fang M; Guo S; Zhang P; Wang L; Wang L; Yu Y
Int Immunopharmacol; 2012 Dec; 14(4):665-73. PubMed ID: 23063973
[TBL] [Abstract][Full Text] [Related]
48. Mucosal immunization with high-mobility group box 1 in chitosan enhances DNA vaccine-induced protection against coxsackievirus B3-induced myocarditis.
Wang M; Yue Y; Dong C; Li X; Xu W; Xiong S
Clin Vaccine Immunol; 2013 Nov; 20(11):1743-51. PubMed ID: 24027262
[TBL] [Abstract][Full Text] [Related]
49. Inhibition of coxsackievirus B3 replication by small interfering RNAs requires perfect sequence match in the central region of the viral positive strand.
Yuan J; Cheung PK; Zhang HM; Chau D; Yang D
J Virol; 2005 Feb; 79(4):2151-9. PubMed ID: 15681418
[TBL] [Abstract][Full Text] [Related]
50. MicroRNA-22-3p displaces critical host factors from the 5' UTR and inhibits the translation of Coxsackievirus B3 RNA.
Rani P; George B; V S; Biswas S; V M; Pal A; Rajmani RS; Das S
J Virol; 2024 Feb; 98(2):e0150423. PubMed ID: 38289119
[TBL] [Abstract][Full Text] [Related]
51. Coxsackievirus B3-induced chronic myocarditis in outbred NMRI mice.
Merkle I; Tonew M; Glück B; Schmidtke M; Egerer R; Stelzner A
J Hum Virol; 1999; 2(6):369-79. PubMed ID: 10774554
[TBL] [Abstract][Full Text] [Related]
52. Sex differences in coxsackievirus B3-induced myocarditis: IL-12Rbeta1 signaling and IFN-gamma increase inflammation in males independent from STAT4.
Frisancho-Kiss S; Nyland JF; Davis SE; Frisancho JA; Barrett MA; Rose NR; Fairweather D
Brain Res; 2006 Dec; 1126(1):139-47. PubMed ID: 16949558
[TBL] [Abstract][Full Text] [Related]
53. Blockade of interleukin-17A protects against coxsackievirus B3-induced myocarditis by increasing COX-2/PGE2 production in the heart.
Xie Y; Chen R; Zhang X; Yu Y; Yang Y; Zou Y; Ge J; Chen H; Garzino-Demo A
FEMS Immunol Med Microbiol; 2012 Apr; 64(3):343-51. PubMed ID: 22141571
[TBL] [Abstract][Full Text] [Related]
54. Dpep2 Emerging as a Modulator of Macrophage Inflammation Confers Protection Against CVB3-Induced Viral Myocarditis.
Yang X; Yue Y; Xiong S
Front Cell Infect Microbiol; 2019; 9():57. PubMed ID: 30899700
[TBL] [Abstract][Full Text] [Related]
55. FTY720 alleviates coxsackievirus B3-induced myocarditis and inhibits viral replication through regulating sphingosine 1-phosphate receptors and AKT/caspase-3 pathways.
Wang X; Li M; Yu Y; Liu G; Yu Y; Zou Y; Ge J; Chen R
J Cell Physiol; 2019 Aug; 234(10):18029-18040. PubMed ID: 30843214
[TBL] [Abstract][Full Text] [Related]
56. Effect of verapamil on acute coxsackievirus B3 murine myocarditis.
Xu Y; Yang YZ; Chen HZ; Jin PY; Guo Q; Zhao WZ; Yang JH; Cai QX; Zhou YC
Chin Med J (Engl); 1992 Oct; 105(10):818-21. PubMed ID: 1337875
[TBL] [Abstract][Full Text] [Related]
57. Pyrrolidine dithiocarbamate reduces coxsackievirus B3 replication through inhibition of the ubiquitin-proteasome pathway.
Si X; McManus BM; Zhang J; Yuan J; Cheung C; Esfandiarei M; Suarez A; Morgan A; Luo H
J Virol; 2005 Jul; 79(13):8014-23. PubMed ID: 15956547
[TBL] [Abstract][Full Text] [Related]
58. A phosphorothioate antisense oligodeoxynucleotide specifically inhibits coxsackievirus B3 replication in cardiomyocytes and mouse hearts.
Yuan J; Cheung PK; Zhang H; Chau D; Yanagawa B; Cheung C; Luo H; Wang Y; Suarez A; McManus BM; Yang D
Lab Invest; 2004 Jun; 84(6):703-14. PubMed ID: 15094712
[TBL] [Abstract][Full Text] [Related]
59. Early Treatment of Coxsackievirus B3-Infected Animals With Soluble Coxsackievirus-Adenovirus Receptor Inhibits Development of Chronic Coxsackievirus B3 Cardiomyopathy.
Pinkert S; Dieringer B; Klopfleisch R; Savvatis K; Van Linthout S; Pryshliak M; Tschöpe C; Klingel K; Kurreck J; Beling A; Fechner H
Circ Heart Fail; 2019 Nov; 12(11):e005250. PubMed ID: 31718319
[TBL] [Abstract][Full Text] [Related]
60. [The mechanisms responsible for the therapeutic effects of anti-Fas ligand antibody on viral myocarditis in mice].
Chang H; Han B; Han XZ
Zhonghua Er Ke Za Zhi; 2005 Dec; 43(12):920-4. PubMed ID: 16412356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
